Ö×ÁöÉú³¤²»½öÈ¡¾öÓÚ¶ñÐÔÖ×Áöϸ°ûµÄÒÅ´«¸Ä±ä£¬Ò²È¡¾öÓÚ»ùÖÊ¡¢Ñª¹Ü¡¢½þÈóÑ×֢ϸ°ûµÈÖ×Áö΢»·¾³(TME£¬tumor microenvironment)µÄ¸Ä±ä¡£²»ÉÙÑо¿±íÃ÷Ö×Áö¸Éϸ°ûÊÇÖ×ÁöÄÍÒ©¡¢¸´·¢ºÍ×ªÒÆµÄ¸ùÔ´£¬Òò´ËÉîÈëÑо¿Ö×ÁöÑ×ÐÔ΢»·¾³¶ÔÖ×Áö¸Éϸ°ûµÄµ÷¿Ø»úÖÆ£¬Ò²Ðí½«ÓÐÖúÓÚ¿ÆÑ§¼ÒÃÇÕÒµ½Ç±ÔÚµÄÖÎÁưеã¡£

½üÆÚÀ´×ÔÖпÆÔºÉϺ£°Í˹µÂÑо¿Ëù£¬ÉϺ£ÖÐÒ½Ò©´óѧµÈ´¦µÄÑо¿ÈËÔ±½ÒʾÁËIÐ͸¨ÖúÐÔTϸ°ûÑùµÄµ÷½ÚÐÔTϸ°û£¨Th1-like Treg£©ÔÚÌåÄڵķ¢Éú»úÖÆ£¬Õâ¶ÔÓÚ´òÆÆÖ×Áö΢»·¾³ÖеÄÃâÒßÄÍÊܾßÓÐDZÔÚÁÙ´²Ó¦ÓüÛÖµ¡£

ÕâÒ»Ñо¿³É¹û¹«²¼ÔÚ11ÔÂ18ÈÕµÄNature CommunicationsÔÓÖ¾ÉÏ£¬ÎÄÕµÄͨѶ×÷ÕßÊÇÉϺ£°Í˹µÂÑо¿ËùµÄÀî±óÑо¿Ô±£¬ÆäÑо¿×鳤ÆÚÖÂÁ¦ÓÚÑо¿ÈËÌåÃâÒßϵͳÈçºÎµ÷½Ú½¡¿µÓë¼²²¡£¬°üÀ¨²¡¶¾ÀഫȾÐÔ¼²²¡£¬×ÔÉíÃâÒßÐÔ¼²²¡ºÍ°©Ö¢·¢ÉúµÄϸ°û¼°·Ö×Ó»úÀí¡£ÎÄÕµÚÒ»×÷ÕßΪ·Ö×ÓÃâÒßѧ¿ÎÌâ×鲩ʿÑо¿ÉúÀîÑïÑïºÍÉϺ£ÖÐÒ½Ò©´óѧҩѧԺÂÀ«h²©Ê¿¡£

µ÷½ÚÐÔT£¨Treg£©Ï¸°ûά³Ö×ÅÌåÄÚÃâÒßÎÈ̬£¬ÒÖÖÆ¹ý¶È¼¤»îµÄÃâÒß·´Ó¦¡£Tregϸ°ûµÄÎȶ¨ÐÔÓë¿ÉËÜÐÔ¹ØÏµµ½¶àÖÖÃâÒßÐÔ¼²²¡µÄ·¢ÉúºÍ·¢Õ¹¡£ÆäÖУ¬Tregϸ°û¹¦ÄÜÎȶ¨ÐÔÊܵ½¶àÖÖ°ûÍâÐźŵ÷½Ú£¬ÀýÈçϸ¾úÖ¬¶àÌÇ£¨LpS£©¡¢IL-1¦ÂºÍÈȼ¤»î£¨heat shock£©µÈÐźÅÄÜÓÕµ¼Tregϸ°û¹Ø¼üת¼Òò×ÓFOXp3µ°°×µÄ·ºËØ»¯½µ½â¡£µ«ÊÇ£¬ÌåÄÚµ÷¿ØFOXp3+Tregϸ°ûÎȶ¨ÐԵĻúÖÆÄ¿Ç°Éв»Çå³þ¡£

ÔÚÕâÆªÎÄÕÂÖУ¬Ñо¿ÈËÔ±ÀûÓÃTregϸ°ûÖÐÌØÒìÐÔÇóýÈ¥·ºËØ»¯Ã¸Usp21»ùÒòµÄСÊ󣬷¢ÏÖСÊó¸ÎÔà¡¢·ÎºÍÍÙÒºÏÙµÈÆ÷¹ÙÖÐUsp21»ùÒòȱÏݵÄTregϸ°û·ÖÃÚ´óÁ¿µÄÑ×Ö¢Òò×ÓIFN-¦Ã¡£Í¬Ê±ÌåÍâ·Ö»¯ÊµÑéҲ֤ʵ¸Ãϸ°û±äµÃ¸üÏñIÐ͸¨ÖúÐÔT£¨Th1£©Ï¸°û¡£

Ñо¿ÈËÔ±½øÒ»²½»¹·¢ÏÖ£¬USp21ͨ¹ýÈ¥·ºËØ»¯ÐÞÊÎÀ´ÒÖÖÆ¹Ø¼üת¼Òò×ÓFOXp3µ°°×µÄ½µ½â£¬´Ó¶øÎȶ¨Tregϸ°û¡£Òò´Ë£¬ÔÚÌåÄÚ£¬FOXp3²»Îȶ¨µÄTregϸ°û¾ßÓзÖÃÚ´óÁ¿Th1ÐÍϸ°ûÒò×ÓµÄÄÜÁ¦£¬²¢½øÒ»²½ÓÕ·¢¹ý¶È¼¤»îµÄºóÐøTh1ÐÍÃâÒß·´Ó¦¡£

½üÆÚÑо¿³É¹ûÏÔʾ£¬½á³¦°©»¼ÕßÌåÄڵͱí´ïFOXp3µÄTregϸ°û·ÖÃÚ¸ü¶àµÄÑ×ÐÔϸ°ûÒò×ÓIFN-¦Ã£¬²¢Ô¤Ê¾½á³¦°©»¼Õ߸üºÃ´æ»îÂÊ¡£Òò´Ë£¬Õë¶ÔÈ¥·ºËØ»¯Ã¸USp21µÄС·Ö×ÓÒÖÖÆ¼ÁÓпÉÄÜ»áÔÚÖ×Áö΢»·¾³ÖÐÓÕµ¼²úÉú¸ü¶àµÄTh1-like Tregϸ°û£¬¸üÓÐÀûÓÚ´òÆÆÖ×Áö΢»·¾³ÖеÄÃâÒßÄÍÊÜ£¬ÔöÇ¿¿¹Ö×ÁöÃâÒß·´Ó¦¡£

һЩ¿ÆÑ§¼Ò´Ó²»Í¬µÄ·½Ã桰Χ»÷¡±Ö×Áö΢»·¾³£¬À´×ÔÒÁÀûŵÒÁ´óѧµÄÒ»ÏîÑо¿·¢ÏÖÔÚ¶ñÐÔÖ×ÁöÖУ¬Ö»ÓÐÉÙÊýÖ×Áöϸ°ûÄܹ»ÌÓÍѺÍÀ©É¢µ½ÉíÌåµÄÆäËû²¿Î»£¬µ«ÊÇ£¬ÑØ×ÅÖ×Áö±ßÔµµÄÇúÏߣ¬¿ÉÄܶÔÓÚ¼¤»îÕâЩÖ×ÁöÖÖֲϸ°û£¬Æðµ½Á˺ܴóµÄ×÷Óá£

Ñо¿ÈËÔ±ÔÚËûÃǵŤ³Ì»·¾³ÖÐ×öÁË´óÁ¿µÄ²âÊÔ£¬ÒÔÈ·ÈÏÖ×Áö´«²¥ÄÜÁ¦£¬±ÈÈçÒÅ´«·ÖÎö¡£ËûÃÇ»¹²âÊÔÁËÆäËû°©Ï¸°ûϵ¡ª¡ªÈËÀ๬¾±°©¡¢·Î°©ºÍǰÁÐÏÙ°©£¬²¢·¢ÏÖËüÃÇÒÔͬÑùµÄ·½Ê½¶ÔÓÐͼ°¸µÄÖ×Áö»·¾³×ö³öÁË·´Ó¦¡£°©×ªÒƵÄÒ»¸ö×ï¿ý»öÊ×£ºÖ×ÁöÐÎ×´

£¨ÉúÎïͨ£ºÍòÎÆ£©

×÷Õß¼ò½é£º

Àî±ó

¼òÀú£º
1992-1996°²»Õʦ·¶´óѧÉúÎïϵѧʿ £¬1996-2001±±¾©´óѧÉúÃü¿ÆÑ§Ñ§Ôº²©Ê¿£¬ 2001-2006ÃÀ¹ú±öÎ÷·¨ÄáÑÇ´óѧҽѧԺ²¡Àí¼°ÊµÑéҽѧϵ²©Ê¿ºó¡£ 2002-2003Ó¢¹úÅ£½ò´óѧ Sir William Dunn²¡ÀíѧԺ Ñо¿·ÃÎÊѧÕߣ¬ 2006-2009ÃÀ¹ú±öÎ÷·¨ÄáÑÇ´óѧҽѧԺ²¡Àí¼°ÊµÑéҽѧϵ¸ß¼¶Ñо¿ÖúÀí £¬ÏÖ±»Æ¸ÎªÖйú¿ÆÑ§ÔºÉϺ£°Í˹µÂÑо¿Ëù·Ö×ÓÃâÒßѧʵÑéÊÒ Ñо¿×鳤£¬Ñо¿Ô± ¡£ÃÀ¹úÃâÒßѧ¼Òѧ»á»áÔ± £¨Member, AAI£© £¬ÃÀ¹ú°©Ö¢Ñо¿Ñ§»á»áÔ± £¨Associate Member, AACR£©£¬Å¦Ô¼¿ÆÑ§Ñ§Ôº»áÔ± £¨Associate Member, NYAS£©£¬¿Í×ù±à¼­ ¡¶ÃâÒßѧÑо¿¡·2008£¨Guest Editor, Immunological Research£© 2007-2008»ñµÃÃÀ¹ú³²ÊÏʵÑéÊÒÓÐÏÞ¹«Ë¾£¨Nidus Laboratories, Inc.£©¿ÆÑÐ×ÊÖúÏîÄ¿¡£

Ñо¿·½Ïò¼°ÄÚÈÝ£º
ÎÒÃǽ«³¤ÆÚÖÂÁ¦ÓÚÑо¿ÈËÌåÃâÒßϵͳÈçºÎµ÷½Ú½¡¿µÓë¼²²¡£¬°üÀ¨²¡¶¾ÀഫȾÐÔ¼²²¡£¬×ÔÉíÃâÒßÐÔ¼²²¡ºÍ°©Ö¢·¢ÉúµÄϸ°û¼°·Ö×Ó»úÀí¡£Ïֽ׶Σ¬ÎÒÃǼ¯ÖÐÑо¿¾ßÓÐÃâÒßµ÷½Ú¹¦ÄܵÄTϸ°ûµÄÒ»¸öÑÇȺ£¬¼´CD4+CD25+FOXp3+µ÷½ÚÐÔTϸ°ûÔÚÈËÀàÖØ´ó²¡¶¾ÐÔ´«È¾²¡°üÀ¨°¬×̲¡£¬ÒÒÐͼ°±ûÐͲ¡¶¾ÐÔ¸ÎÑ×ÖеÄÉúÀí¹¦Äܼ°Æäµ÷½Ú»úÀí¡£
Forkheadת¼Òò×Ó¼Ò×å³ÉÔ±FOXp3µÄ±í´ïˮƽ£¬×´Ì¬¼°Æä»îÐÔ¾ö¶¨Á˵÷½ÚÐÔTϸ°ûµÄÃâÒßµ÷½Ú»îÐÔ¡£Ò»·½Ã棬ÔÚ¸ÐȾÐÔ¼²²¡·¢ÉúÔçÆÚ£¬FOXp3+µ÷½ÚÐÔTϸ°û¶ÔЧӦÐÔTϸ°ûµÄÒÖÖÆÐ§Ó¦¿ÉÄܻᵼÖÂÃâÒßϵͳɥʧ¶Ô¸ÐȾµÄÃâÒß¿ØÖÆ£»ÁíÒ»·½Ã棬µ÷½ÚÐÔTϸ°ûµÄÃâÒßÒÖÖÆÐ§Ó¦¶ÔÓÚ±ÜÃâ¹ý¶ÈÃâÒß·´Ó¦µ¼ÖÂ×éÖ¯ËðÉËÓֺܿÉÄÜÊÇÖÁ¹ØÖØÒªµÄ¡£
¶ÔFOXp3Éú»¯»îÐÔ£¬ÉúÀí¹¦Äܼ°Æäµ÷¿ØµÄÉîÈëÀí½â£¬¶ÔÓÚÖÎÁÆÐÔ¿ØÖÆÈËÌåÄÚµ÷½ÚÐÔTϸ°ûµÄÃâÒß»îÐÔÖÁ¹ØÖØÒª£¬´Ó¶ø´Ù½ø²¡¶¾ÀഫȾÐÔ¼²²¡²¡È˰üÀ¨°¬×̲¡¶¾¸ÐȾÕß»ò°¬×̲¡»¼Õß,ÒÒÐͺͱûÐͲ¡¶¾ÐÔ¸ÎÑ×»¼ÕߵĿµ¸´¡£»ùÓÚ×î½ü¼¸ÄêÀ´µÄ¹¤×÷(Ïê¼û×ÛÊöImmunol Rev 212:99-113; Curr Opin Immunol 19(5):589-95; Cell Cycle 15;6(12):1432-6; and Immunology 123(1):17-9)£¬ÎÒÃÇÏÖ½×¶ÎÌá³öÈçϼÙ˵£ºÔÚµ÷½ÚÐÔTϸ°ûÖУ¬FOXp3µÄ»îÐԺ͹¦ÄÜ1) ÔÚ²¡¶¾¸ÐȾ¹ý³ÌÖÐÊܵ½»úÌåÄÚ¸÷ÖÖÉúÀíÐźŵÄʱ¿Õµ÷¿Ø£»2) ÒÀÀµÓÚFOXp3µ°°×µÄ·­ÒëºóÐÞÊε÷¿Ø£»3) »¹ÒÀÀµÆäת¼¸´ºÏÌåÖÐÆäËüת¼Òò×Ó¼°»îÐÔøÀàµÄ¶¯Ì¬×é×°¼°ÑÇϸ°û¶¨Î»¡£
ÎÒÃǽ«»áÑ¡ÔñÐÔµØÀûÓ÷Ö×Ó£¬Éú»¯£¬½á¹¹£¬ÔÚϸ°ûˮƽÉÏ»ùÓÚ¶àÖØºÍ¿ÉÓÕµ¼ÐÔRNAÒÖÖÆ£¬ÒÔ¼°ÌåÄÚµÄʵÑ鶯ÎïÄ£Ð͵ȶàÖØÊÖ¶ÎÀ´ÑéÖ¤ÎÒÃǵļÙÉ裬´Ó¶øÉîÈëÑо¿µ÷½ÚÐÔTϸ°ûÔÚ¸ÐȾÐÔ¼²²¡·¢Éú²»Í¬½×¶ÎÖеĸ÷ÖÖÉúÀí¹¦ÄÜ£º
(1) ÉîÈë¼ø¶¨FOXp3ת¼¸´ºÏÌåÖеĸ÷¸ö¹Ø¼ü×é·Ý£¬ÆäÉÏÓÎÐźÅͨ·£¬ÏÂÓÎЧӦ·Ö×Ó×é·Ý£¬ÒÔ¼°ËüÃÇÔÚ µ÷½ÚÐÔTϸ°ûÖ÷µ¼µÄÃâÒßµ÷½ÚÖеÄÉúÀí¹¦ÄÜ¡£
(2) ÔÚ¸ÐȾÐÔ¼²²¡·¢ÉúµÄ²»Í¬½×¶Î£¬Ï¸°ûÍâÐźÅ(ÀýÈçTϸ°ûÊÜÌåÐźÅͨ·£¬TLRÐźÅͨ·£¬¸ÐȾÐÔϸ°ûÒò×ÓÊÜÌåÐźÅͨ·)¶Ôµ÷½ÚÐÔTϸ°ûÖеÄFOXp3µ°°×µÄÎȶ¨ÐÔ¼°×ªÂ¼¸´ºÏÌ嶯̬×é×°µÄµ÷¿Ø¡£
(3) ÔÚ²¡¶¾ÐÔ¼²²¡(ÀýÈçHIV¸ÐȾ£¬HBV¸ÐȾ£¬HCV¸ÐȾ)·¢ÉúµÄ¹ý³ÌÖв¡¶¾ËÞÖ÷Ï໥×÷Ó㬲¡¶¾Ö²¡·Ö×Ó»úÖÆ£¬ÌرðÊDz¡¶¾Òò×Ó¶Ôµ÷½ÚÐÔTϸ°ûÖÐFOXp3µ°°×µÄ·­ÒëºóÐÞÊε÷¿Ø¼°Æä¹¦Äܵĵ÷½Ú¡£

Ô­ÎÄÕªÒª£º

USp21 prevents the generation of T-helper-1-like Treg cells

FOXp3+ Regulatory T (Treg) cells play a key role in the maintenance of immune homeostasis and tolerance. Disruption of Foxp3 expression results in the generation of instable Treg cells and acquisition of effector T-cell-like function. Here we report that the E3 deubiquitinase USp21 prevents the depletion of FOXp3 at the protein level and restricts the generation of T-helper-1-like Treg cells. Mice depleted of Usp21 specifically in Treg cells display immune disorders characterized by spontaneous T-cell activation and excessive T-helper type 1 (Th1) skewing of Treg cells into Th1-like Treg cells. USp21 stabilizes FOXp3 protein by mediating its deubiquitination and maintains the expression of Treg signature genes. Our results demonstrate how USp21 prevents FOXp3 protein depletion and controls Treg lineage stability in vivo.